Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 746

Sort by

Sort Order Select

Journal Articles

Protein expression profiling suggests relevance of noncanonical pathways in isolated pulmonary embolism

Blood (2021) 137 (19): 2681–2693.

https://doi.org/10.1182/blood.2019004571

Published: 2021

Includes: Supplemental data

Journal Articles

Targeting a cytokine checkpoint enhances the fitness of armored cord blood CAR-NK cells

May Daher, Rafet Basar, Elif Gokdemir, Natalia Baran, Nadima Uprety, Ana Karen Nunez Cortes, Mayela Mendt, Lucila Nassif Kerbauy, Pinaki P. Banerjee, Mayra Shanley, Nobuhiko Imahashi, Li Li, Francesca Lorraine Wei Inng Lim, Mohsen Fathi, Ali Rezvan, Vakul Mohanty, Yifei Shen, Hila Shaim, Junjun Lu, Gonca Ozcan, Emily Ensley, Mecit Kaplan, Vandana Nandivada, Mustafa Bdiwi, Sunil Acharya, Yuanxin Xi, Xinhai Wan, Duncan Mak, Enli Liu, Xin Ru Jiang, Sonny Ang, Luis Muniz-Feliciano, Ye Li, Jing Wang, Shahram Kordasti, Nedyalko Petrov, Navin Varadarajan, David Marin, Lorenzo Brunetti, Richard J. Skinner, Shangrong Lyu, Leiser Silva, Rolf Turk, Mollie S. Schubert, Garrett R. Rettig, Matthew S. McNeill, Gavin Kurgan, Mark A. Behlke, Heng Li, Natalie W. Fowlkes, Ken Chen, Marina Konopleva, Richard E. Champlin, Elizabeth J. Shpall, Katayoun Rezvani

Blood (2021) 137 (5): 624–636.

https://doi.org/10.1182/blood.2020007748

Published: 2021

Includes: Supplemental data

Journal Articles

Evaluation of the Functional Landscape of Systemic Immunity in Classical Hodgkin Using a Novel Single Cell Platform (Isolight)

Catherine Diefenbach, MD, Linda Lam, PhD, Bruce G. Raphael, MD, Kenneth B. Hymes, MD, Michael L. Grossbard, MD, Tibor Moskovits, MD, Peter Martin, FRCPC, MD MS, Jia Ruan, MD PhD, John P. Leonard, MD, Pratip Chattopadhyay, PhD

Blood (2019) 134 (Supplement_1): 3980.

https://doi.org/10.1182/blood-2019-128366

Published: 2019

Journal Articles

Reversible DNA Hypermethylation of the Interleukin-15 (IL-15) Promoter Induces IL-15 Expression, Drives the Pathogenesis of T-Cell Large Granular Lymphocytic Leukemia and Provides a Potential Therapeutic Approach Using 5-Azacitidine

Jonathan E Brammer, MD, Amy E Boles, BS, Anthony Mansour, MD, Aharon G. Freud, MD PhD, Monique Mathé-Allainmat, Agnès Quéméner, Erwan Mortier, Pierluigi Porcu, MD, Anjali Mishra, PhD

Blood (2019) 134 (Supplement_1): 3776.

https://doi.org/10.1182/blood-2019-131174

Published: 2019

Journal Articles

Transgenic Expression of IL15 in CD123-Specific BiTE-Secreting Engager T-Cells Results in Improved Anti-AML Activity

Hong Mu-Mosley, MD PhD, Lauren B Ostermann, Muharrem Muftuoglu, MD, Wendy Schober, Nalini B Patel, Abishek Vaidya, MS, Challice L. Bonifant, MD PhD, Stephen Gottschalk, MD, Mireya Paulina Velasquez, MD, Michael Andreeff, MD PhD

Blood (2019) 134 (Supplement_1): 3917.

https://doi.org/10.1182/blood-2019-125928

Published: 2019

Journal Articles

Transcriptome Sequencing Demonstrates Unique Signature Associated with Durable Clinical Response to DC/AML Fusion Vaccine

Blood (2019) 134 (Supplement_1): 3832.

https://doi.org/10.1182/blood-2019-129451

Published: 2019

Journal Articles

Enhancing the Effect of CLL-1 CAR T Cells with Interleukin-15 for Treatment of Acute Myeloid Leukemia

Pinar Ataca Atilla, MD, Haruko Tashiro, MD PhD, Mary Kathryn McKenna, PhD, Madhuwanti Srinivasan, Brian Wesley Simons, Alexandra McLean Stevens, MD PhD, Michele Redell, MD PhD, Maksim Mamonkin, PhD, Malcolm K. Brenner, MD PhD, Erden Atilla, MD

Blood (2019) 134 (Supplement_1): 3912.

https://doi.org/10.1182/blood-2019-127953

Published: 2019

Journal Articles

Initial Findings of the Phase 1 Trial of PBCAR0191, a CD19 Targeted Allogeneic CAR-T Cell Therapy

Caron A. Jacobson, MD, Alex F. Herrera, MD, Lihua E Budde, MD PhD, Daniel J. DeAngelo, MD, Christopher Heery, MD, Anthony Stein, MD, Michael D. Jain, MD PhD, Bijal Shah, MD

Blood (2019) 134 (Supplement_1): 4107.

https://doi.org/10.1182/blood-2019-128203

Published: 2019

Journal Articles

The Lymphoma Tumor Microenvironment Influences Toxicity after CD19 CAR T Cell Therapy

Michael D. Jain, MD PhD, Rawan Faramand, MD, Verena Staedtke, MD PhD, Renyuan Bai, MBBS, Sae Bom Lee, Hiroshi Kotani, MD PhD, Kayla Reid, Kristen Spitler, Julio Chavez, Bijal Shah, MD, Christina A Bachmeier, PharmD, Marian Dam, ARNP, Brigett Brandjes, PA, Ricardo J Gonzalez, MD, John E Mullinax, MD PhD, Xuefeng Wang, PhD, Mohammad Hussaini, MD, Frederick L. Locke, MD, Marco L. Davila, MD PhD

Blood (2019) 134 (Supplement_1): 4105.

https://doi.org/10.1182/blood-2019-127305

Published: 2019

Journal Articles

Immune Monitoring of CD34+ Placental Cell Derived Natural Killer Cell Therapy (PNK-007) in Phase I Study of Multiple Myeloma

William Van Der Touw, Lin Kang, PhD, Joseph Dennis Tario, PhD, Bhavani Stout, Vanessa Voskinarian-Berse, Valentina Rousseva, Paul K. Wallace, MS, PhD, Robert Hariri, MD PhD, Xiaokui Zhang, PhD

Blood (2019) 134 (Supplement_1): 4457.

https://doi.org/10.1182/blood-2019-124509

Published: 2019

Journal Articles

Syndecan-1 Is Critical in ARF6-Dependent Macropinocytosis Driven By KRAS Mutation in the Pathophysiology of Multiple Myeloma

Tengteng Yu, MD PhD, Liang Lin, PhD, Kenneth Wen, Lijie Xing, MD, Jiye Liu, PhD, Shih-Feng Cho, MD PhD, Phillip Hsieh, Ola Rizq, MD PhD, Yuyin Li, PhD, Liang Yu, Xiang Wu, Eugenio Morelli, MD, Yan Xu, MD, Gang An, MD, Nikhil C. Munshi, MD, Lugui Qiu, MD PhD, Kenneth C. Anderson, MD, Yu-Tzu Tai, PhD

Blood (2019) 134 (Supplement_1): 4371.

https://doi.org/10.1182/blood-2019-127454

Published: 2019

Journal Articles

Restoring Innate and Adaptive Immune Repertoire in Multiple Myeloma for Therapeutic Application

Rafael Alonso Fernández, MD, Laetitia Pierre-Louis, Rao Prabhala, Yan Xu, MD, Joaquin Martinez-Lopez, MD PhD, Takahiro Miyazaki, Mehmet Kemal Samur, PhD, Loui Madakamutil, Mariateresa Fulciniti, PhD, Nikhil C. Munshi, MD

Blood (2019) 134 (Supplement_1): 4398.

https://doi.org/10.1182/blood-2019-128767

Published: 2019

Journal Articles

A Phase 1, Open-Label, Multi-Center, Dose Escalation and Dose Expansion Study of NKTR-255 As a Single Agent in Relapsed or Refractory Hematologic Malignancies and in Combination with Daratumumab As a Salvage Regimen for Multiple Myeloma

Nina D. Shah, MD, Cameron J. Turtle, MBBS, PhD, Andrew J. Cowan, MD, Julio C. Chavez, MD, Lihua E Budde, MD PhD, Mario Q. Marcondes, MD PhD, Zachary Lee, PharmD, Wei Lin, MD, Jonathan Zalevsky, Mary Tagliaferri, MD, Krina K. Patel, MDMSc

Blood (2019) 134 (Supplement_1): 4459.

https://doi.org/10.1182/blood-2019-122494

Published: 2019

Journal Articles

Tipifarnib Modulates Interferon (IFN)-γ-Inducible Genes in Acute Myeloid Leukemia

Jayakumar Vadakekolathu, PhD, Stephen Reeder, BSc, Clare Coveney, PhD, Sergio Rutella, MDPhDFRCPath

Blood (2019) 134 (Supplement_1): 2726.

https://doi.org/10.1182/blood-2019-124717

Published: 2019

Journal Articles

Preclinical Characterization of Prgn-3006 Ultracar-T™ for the Treatment of AML and MDS: Non-Viral, Multigenic Autologous CAR-T Cells Administered One Day after Gene Transfer

Tim Chan, PhD, Xiaohong Ma, Fernando Carvajal-Borda, DVM, Jose Velez, Jacques Plummer, Lindsey Shepard, Rutul R Shah, David A Sallman, MD, Helen Sabzevari, PhD

Blood (2019) 134 (Supplement_1): 2660.

https://doi.org/10.1182/blood-2019-130617

Published: 2019

Journal Articles

T Cells Educated By DC/AML Fusions in the Context of 4-1BB Costimulation As a Potent Strategy for Adoptive Cellular Therapy

Jessica Liegel, MD, Dina Stroopinsky, PhD, Haider Ghiasuddin, Adam Morin, Marzia Capelletti, PhD MMSc, Shira Orr, PhD, Maryam Rahimian, MD, Lina Bisharat, Shufen Meng, MD, Myrna Nahas, MD, Matthew Weinstock, MD, Donald Kufe, MD, Jacalyn Rosenblatt, MD, David E. Avigan, MD

Blood (2019) 134 (Supplement_1): 2673.

https://doi.org/10.1182/blood-2019-131491

Published: 2019

Journal Articles

Local Manufacture of CD19 CAR-T Cells Using an Automated Closed-System: Robust Manufacturing and High Clinical Efficacy with Low Toxicities

Blood (2019) 134 (Supplement_1): 2625.

https://doi.org/10.1182/blood-2019-130370

Published: 2019

Journal Articles

Phase 1 Trial of Human IL-15 (rhIL-15) and Obinutuzumab for Relapsed and Refractory Chronic Lymphocytic Leukemia

Milos D. Miljkovic, MDMSc, Kevin C Conlon, MD, Jennifer Hsu, RN, Clare Sun, MD, Adrian Wiestner, MD PhD, Thomas A. Waldmann, MD

Blood (2019) 134 (Supplement_1): 3052.

https://doi.org/10.1182/blood-2019-130807

Published: 2019

Journal Articles

Gene Expression and Cytokine Analyses Identify Markers of Progression from CLL-like Monoclonal B-Cell Lymphocytosis to Chronic Lymphocytic Leukemia

Gonzalo Blanco, PhD, Anna Puiggros, PhD, Barbara Sherry, PhD, Lara Nonell, Eulalia Puigdecanet, Pui Yan Chiu, Yasmine Kieso, MSCR, Gerardo Ferrer, PhD, Magdalena Arnal, María Rodríguez-Rivera, Eva Gimeno, MD PhD, Eugenia Abella, Kanti R Rai, MD, Pau Abrisqueta, MD PhD, Xavier Calvo, MD PhD, Francesc Bosch, MD PhD, Ana Ferrer, MD PhD, Nicholas Chiorazzi, MD, Blanca Espinet, PhD

Blood (2019) 134 (Supplement_1): 3027.

https://doi.org/10.1182/blood-2019-122038

Published: 2019

Journal Articles

Blockade of IL-15 Utilizing Bnz-1, a Selective γ-Chain Inhibiting Peptide, Is Safe and Has Clinical Activity in Patients with T-Cell Large Granular Lymphocytic Leukemia (T-LGLL): Results of a Phase I/II Multi-Center Clinical Trial

Jonathan E. Brammer, MD, Lubomir Sokol, MD PhD, Yutaka Tagaya, MD PhD, Kerry Rogers, Anjali Mishra, PhD, Thomas A. Waldmann, MD, Nazli Azimi, PhD PharmD, Paul Frohna, MD PhD PharmD, Anoshie Ratnayake, MD, Thomas P Loughran, Jr., MD, Karen Ballen, MD

Blood (2019) 134 (Supplement_1): 2835.

https://doi.org/10.1182/blood-2019-129291

Published: 2019

NARROW

Protein expression profiling suggests relevance of noncanonical pathways in isolated pulmonary embolism

Targeting a cytokine checkpoint enhances the fitness of armored cord blood CAR-NK cells

Evaluation of the Functional Landscape of Systemic Immunity in Classical Hodgkin Using a Novel Single Cell Platform (Isolight)

Reversible DNA Hypermethylation of the Interleukin-15 (IL-15) Promoter Induces IL-15 Expression, Drives the Pathogenesis of T-Cell Large Granular Lymphocytic Leukemia and Provides a Potential Therapeutic Approach Using 5-Azacitidine

Transgenic Expression of IL15 in CD123-Specific BiTE-Secreting Engager T-Cells Results in Improved Anti-AML Activity

Transcriptome Sequencing Demonstrates Unique Signature Associated with Durable Clinical Response to DC/AML Fusion Vaccine

Enhancing the Effect of CLL-1 CAR T Cells with Interleukin-15 for Treatment of Acute Myeloid Leukemia

Initial Findings of the Phase 1 Trial of PBCAR0191, a CD19 Targeted Allogeneic CAR-T Cell Therapy

The Lymphoma Tumor Microenvironment Influences Toxicity after CD19 CAR T Cell Therapy

Immune Monitoring of CD34+ Placental Cell Derived Natural Killer Cell Therapy (PNK-007) in Phase I Study of Multiple Myeloma

Syndecan-1 Is Critical in ARF6-Dependent Macropinocytosis Driven By KRAS Mutation in the Pathophysiology of Multiple Myeloma

Restoring Innate and Adaptive Immune Repertoire in Multiple Myeloma for Therapeutic Application

A Phase 1, Open-Label, Multi-Center, Dose Escalation and Dose Expansion Study of NKTR-255 As a Single Agent in Relapsed or Refractory Hematologic Malignancies and in Combination with Daratumumab As a Salvage Regimen for Multiple Myeloma

Tipifarnib Modulates Interferon (IFN)-γ-Inducible Genes in Acute Myeloid Leukemia

Preclinical Characterization of Prgn-3006 Ultracar-T™ for the Treatment of AML and MDS: Non-Viral, Multigenic Autologous CAR-T Cells Administered One Day after Gene Transfer

T Cells Educated By DC/AML Fusions in the Context of 4-1BB Costimulation As a Potent Strategy for Adoptive Cellular Therapy

Local Manufacture of CD19 CAR-T Cells Using an Automated Closed-System: Robust Manufacturing and High Clinical Efficacy with Low Toxicities

Phase 1 Trial of Human IL-15 (rhIL-15) and Obinutuzumab for Relapsed and Refractory Chronic Lymphocytic Leukemia

Gene Expression and Cytokine Analyses Identify Markers of Progression from CLL-like Monoclonal B-Cell Lymphocytosis to Chronic Lymphocytic Leukemia

Blockade of IL-15 Utilizing Bnz-1, a Selective γ-Chain Inhibiting Peptide, Is Safe and Has Clinical Activity in Patients with T-Cell Large Granular Lymphocytic Leukemia (T-LGLL): Results of a Phase I/II Multi-Center Clinical Trial

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only